What's Crossing the Border

Drug pricing has been a defining fight in biopharma for more than a decade. It became a public reckoning when Gilead's hepatitis C cure Sovaldi launched at roughly $1,000 a pill in late 2013, hardened into law with the Inflation Reduction Act in 2022, and reached a new pitch in 2026. Most-favored-nation pricing is its newest front: tying what the United States pays to the lower prices other wealthy countries negotiate. It is often spoken of in the same breath as the Medicare drug price negotiation program, the IRA instrument the Supreme Court let stand in May 2026 when it declined the first wave of manufacturer challenges. The two are related but distinct, and worth holding apart even as they converge.

‍

With the constitutional challenge declined and the negotiation program moving into permanent rule, the legal questions that might have reshaped the system from outside are largely settled. The contest has moved inside, to the quality of the evidence case: therapeutic advance, comparative effectiveness, unmet need, and the specific populations a therapy serves. That is what sets a price now, and it is built years before the negotiation, at and after launch.

‍

Beneath the price sits a fiscal-sustainability question every health system is now forcing rather than deferring. The long effort to move the conversation from price to value advanced how therapies are assessed, yet the pressure was always about price.

‍

‍

Why the benchmark moves both ways

Most-favored-nation pricing is usually described as pushing US prices down toward an international benchmark. It is also lifting that benchmark abroad. In December 2025, as part of the UK-US pricing arrangement, NICE raised its cost-effectiveness range for the first time since 1999, and the White House's own analysis names this a template it expects to replicate across other reference nations. The enforcement edge is becoming visible also. In June 2026, the United States opened a Section 301 investigation into Germany's drug-pricing rules, alleging that Americans pay roughly 3.9 times what Germans do.

‍

The Joint Clinical Assessment (JCA), the EU-wide clinical-value review now traveling across member states, tightens the evidence requirement at the same moment most-favored-nation pricing ties US prices to European ones. The compounding of the two is no longer a forecast. It is measured. GlobalData found a 35 percent decline in European launches in the ten months after the US move toward international reference pricing. A study published in June 2026 isolated the specific burden: orphan launches inside the JCA scope declined 22.9 percent, against just 1.4 percent outside it. That gap of more than twenty points separates the cost of JCA preparation from general pricing pressure, and the people who feel it first are patients in the markets deprioritized in a launch sequence.

‍

It is already happening to specific drugs. In February 2026, Amgen pulled Repatha, its PCSK9 inhibitor for LDL cholesterol and cardiovascular risk, from Denmark, even after winning the tender and securing reimbursement, citing changed global pricing conditions. Denmark sits in the new US reference baskets, where competitive tenders run roughly half below list, so a deep, confidential Danish net price could anchor what Medicare pays.

‍

When a US price is tied to what other countries pay, more than a number crosses the border.

‍

‍

What travels beneath the price

There are subtler implications of international transfer. When a US price is tied to countries whose agencies judge value on QALYs and fixed cost-effectiveness thresholds, what crosses the border is not only a lower price. It is also the valuation framework beneath that price: how much a health gain is worth, whether early access carries value on its own, how heavily severity and rarity are weighted, and what even counts as a benefit. Health economists reached the same point in Health Affairs in June 2026: what reference pricing embeds is foreign valuation, not only foreign price. Those are contestable value judgments, made under other health systems and priorities, imported into US pricing on frameworks the United States never debated or adopted.

‍

The exposure runs deeper than geography. Inside the United States, it sits at the level of the indication. Because these are Medicare programs, exposure depends on which indications reach the older, Medicare-eligible population, so reducing it can mean steering a portfolio away from exactly those indications. That is a commercial calculation with a distributional edge, and its consequence falls on patients: it can redirect innovation away from the conditions, and the specific populations, the program exists to serve. Which diseases get the next asset, and which patients are left waiting, is an equity question sitting inside what looks like a pricing one.

‍

‍

The translation era, and who masters it

One evidence base now has to answer to several audiences at once, each reading it through a different lens and on a different clock: the payer, for formulary; the Medicare negotiation, for the cycle that sets a negotiated price; European HTA, local and through the JCA, for the clinical-value bar that increasingly travels; trade policy, for the basket mechanics that set the benchmark; and industrial policy, for the European competitiveness framing now reshaping access. The difficult question is not only how to serve them from one base, but also how to weigh their respective claims on it. For my biopharma strategic advisory clients I have built an integrated matrix to map it, the discipline I call the translation layer: converting pricing-policy mechanics into evidence-strategy decisions, which evidence to mount, to which audience, under which criteria, on which clock.

‍

The pricing era that began with the Inflation Reduction Act and accelerated through most-favored-nation pricing has been read as a confrontation. The first year of the deals, and the close of the first litigation wave, mark something more durable: a translation era. Its test is exacting: whether an evidence base built years before a price is set can still hold its value across every border that now reads it. The companies that master that translation will be the ones whose next asset still reaches the patient waiting for it.